NCI Pilot Trial to Assess Value of Genetic Sequencing for Improving Patient Outcomes
The National Cancer Institute (NCI) has launched a clinical trial to determine whether selecting therapies based on genetic mutations can improve outcomes in patients with metastatic solid tumors. Molecular Profiling based Assignment of Cancer Therapeutics (M-PACT) is one of the first randomized trials to assess if using genetic mutation as the basis for treatment selection can improve the rate and duration of response in patients with advanced-stage solid tumors.
A second goal is to see if the use of genetic sequencing can identify a subpopulation of patients who could benefit from specific targeted treatment, which would help to expedite drug development for these patients based on their genetic profile, and could lead to smaller clinical trials and reduce cost and time of drug development.
â€śPatients will have their tumors genetically screened, and if a predefined mutation is found, they will receive treatment with targeted agents,â€ť said Shivaani Kummar, MD, head of NCIâ€™s Developmental Therapeutics Clinic and the trialâ€™s principal investigator. â€śWhat we donâ€™t know, however, is whether using this approach to assign targeted treatments is really effective at providing clinical benefit to patients, as most tumors have multiple mutations, and itâ€™s not always clear which mutation to target and which agent is most likely to provide maximal benefit.â€ť
The M-PACT trial is designed to determine whether patients with mutations that have been shown in the laboratory to affect drug effectiveness will benefit from a specific targeted therapy, and if this approach results in better outcomes.
The NCI is now screening hundreds of people to select 180 patients with advanced refractory solid tumors based on their genetic profile. u
National Cancer Institute Press Release; January 30, 2014.
On December 3, 2019, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to the biopharmaceutical company Adaptimmune Therapeutics for ADP-A2M4 for the treatment of synovial sarcoma. Earlier this year, the FDA granted Orphan Drug designation to the agent for the treatment of soft tissue sarcomas.
One of the most important studÂÂÂies presented at ASCO 2018 showed that endocrine therapy alone was noninferior to endocrine therapy plus chemotherapy in women with estrogen receptor (ER)-positive, HER2-Ânegative, node-negative early-stage breast cancer and an intermediate risk score (score, 11-25) on the Oncotype DX gene-expression assay for breast cancer. “Application [ Read More ]